Search

Your search keyword '"Mannent, Leda P."' showing total 216 results

Search Constraints

Start Over You searched for: Author "Mannent, Leda P." Remove constraint Author: "Mannent, Leda P."
216 results on '"Mannent, Leda P."'

Search Results

1. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

2. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

8. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

9. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma

10. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

11. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

12. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial

13. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

15. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study

16. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma

17. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study

18. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

21. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis

24. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis

25. Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization

26. Dupilumab in Asia-Pacific patients with persistent asthma

27. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.

28. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

29. Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION

30. Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies

31. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study

34. 344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)

35. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

36. sj-docx-1-aor-10.1177_00034894231176334 – Supplemental material for Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results

37. EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION

38. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

39. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials

41. Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines

42. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

43. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis

44. Dupilumab in CRSwNP : Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

45. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab

46. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials

47. Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients

48. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

Catalog

Books, media, physical & digital resources